Health Care · Services-Commercial Physical & Biological Research

CRL Charles River Laboratories SEC Filings & Insider Trading Activity 2026

company
CIK 1100682116 filings
S&P 500

CRL at a glance

Charles River Laboratories (CRL, SEC CIK 1100682) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 27, 2025 (FY2025), Charles River Laboratories (CRL) reported revenue of $4.0 billion (down 0.9% from FY2024) and a net loss of $144.3 million. Diluted EPS was -$2.91.
  • As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding Charles River Laboratories (CRL) shares worth $6.6 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by FOSTER JAMES C on October 22, 2026 of 24,042 shares at $350.00 per share.
  • In the last 90 days, CRL insiders reported 1 open-market purchase ($3K) and 4 open-market sales ($19.5M) on Form 4, a net sale of $19.5M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$4.0B
−0.9% vs prior year
Insiders · 90 days
1 buy · 4 sells
Net −$19.5M
13F holders
34 funds
$6.6B · +0 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 27, 2025

Full analysis →

Management Discussion & Analysis

  • Revenue DSA declined in fiscal 2025 due to lower study volumes; RMS revenue increased driven by large research models and pricing; Manufacturing Microbial Solutions grew robustly
  • Goodwill impairment of $165M in Biologics Solutions for 2025 due to reduced performance; impairment $215M in 2024 in same unit
  • Best segment: Manufacturing Microbial Solutions with robust growth, share gains, and higher sales; Worst segment: DSA with declined revenue and backlog falling to $1.9B from $2.0B
  • Capital allocation: Acquired KF for $510M, Noveprim controlling interest for $392.4M, SAMDI for $62.8M, PathoQuest option for ~$60M; acquisitions funded by cash and Credit Facility
  • Forward outlook: $300M cost savings by 2026; focus on strategic acquisitions, partnerships, and divestments of 7% 2025 revenue; cautious early-stage R&D spending remains a risk

Business Overview

  • Core business model: Preclinical and clinical laboratory services for drug discovery and development
  • No new products, services, or business segments introduced or emphasized in this fiscal year
  • Maintained existing strategic practices, including strict compliance on timing of equity awards and insider trading policies
  • Fiscal 2025 equity awards policy with no stock options granted near earnings releases to avoid insider trading risks
  • No errors or clawbacks of executive compensation reported during or after fiscal 2025

Risk Factors

  • Cybersecurity risk governance by Board Audit Committee with quarterly reviews and direct CIO, CISO reporting to Audit Chair
  • Heavy reliance on Chief Information Officer with 30+ years experience for global IT risk oversight and digital strategy execution
  • Cybersecurity assessments include third-party audits, vulnerability tests, and industry standard compliance frameworks
  • Incident Response Plan mandates escalation to Audit Committee for significant cybersecurity events
  • No specific regulatory, geopolitical, operational supply chain, competitive, or financial risks detailed in this section

AI summary of the CRL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 26, 2026

Risk Factors

  • No material changes to 2025 Form 10-K risk factors
  • Q1 10-Q risk factor incorporated by reference, with no details repeated this quarter
  • Additional unknown or currently immaterial risks could materially adversely affect results

Management Discussion & Analysis

  • Quarterly revenue $982.7M, down $22.1M or 2.2% YoY
  • Operating margin 20.6% vs 13.3% YoY, operating income $202.6M vs $133.8M
  • Best segment: Manufacturing revenue $178.9M, operating margin 35.7% vs 20.9%
  • Worst segment: RMS revenue $207.5M, down 2.8% YoY, driven by Cell Solutions divestiture
  • Cash $200.4M vs $213.8M, operating cash flow $474.9M vs $590.1M, $300.0M stock repurchases and $467.3M acquisitions through nine months

AI summary of the CRL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Acquisition agreement for Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania
  • Expands Charles River’s drug-development services footprint through added bioanalysis and DMPK capabilities

Item EX-99.1: Item EX-99.1

  • Acquisition price approximately $470 million cash, plus up to $75 million performance-based payments
  • Target includes Frontage’s Exton, Pennsylvania bioanalysis and DMPK operations, two sites, approximately 340 employees
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 financial results released for the period ended September 26, 2026
  • Investors should review Exhibit 99.1 for revenue, earnings, guidance and operating drivers

Item EX-99.1: Item EX-99.1

  • Q3 revenue $982.7M, down 2.2% reported but organic growth 4.7%, signaling underlying demand recovery after divestitures
  • Non-GAAP EPS $3.09, up 27.2%, with operating margin expanding 330 basis points to 23.0%
Filed Sep 24, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor Day materials outline CRL’s business strategy and long-term financial targets through 2030
  • Management reaffirmed full-year 2026 guidance, reducing near-term uncertainty around existing outlook

AI summaries of CRL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CRL

Don't miss the next CRL filing

  • Alerts as it files. A push when CRL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CRL, by share count.
  • Ask anything. An AI agent that reads every CRL filing and answers with sources.

CRL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Knell Michael GunnarFNov 6, 2026$313.02
FOSTER JAMES CSellOct 22, 2026$350.00
FOSTER JAMES CMOct 22, 2026-
FOSTER JAMES CMOct 22, 2026$244.41
Parisotto Shannon MMOct 21, 2026-
Parisotto Shannon MMOct 21, 2026$244.41
Parisotto Shannon MSellOct 21, 2026$344.41
Parisotto Shannon MMOct 5, 2026$208.44

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$4.1B$4.0B$4.0B
Operating Income$617.3M$227.3M$25.2M
Net Income$474.6M$22.2M-$144.3M
Op. Margin14.9%5.6%0.6%
Net Margin11.5%0.5%-3.6%
Balance Sheet
Total Assets$8.2B$7.5B$7.1B
Equity-$3.5B$3.2B
ROE-0.6%-4.6%
Per Share
EPS$9.22$0.20$-2.91
Cash Flow
Operating CF$683.9M$734.6M$737.6M

Source: XBRL data in Charles River Laboratories (CRL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CRL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CRL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202634$6.57B
Q2 202634$6.49B
Q1 202636$4.72B
Q4 202535$4.76B
Q3 202535$3.30B
Q2 202532$2.98B
Q1 202531$2.48B
Q4 202430$2.54B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 267 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CRL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 9, 2026--
8-KNov 9, 2026Analysis-
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
4Oct 26, 2026--
4Oct 23, 2026--
4Oct 7, 2026--
4Oct 2, 2026--
8-KSep 24, 2026Analysis-
4Aug 27, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 13, 2026--
4Aug 13, 2026--
SC 13GAug 13, 2026-
4Aug 11, 2026--
4Aug 11, 2026--
4Aug 10, 2026--
4Aug 10, 2026--
4Aug 6, 2026--
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
4Jul 1, 2026--
4Jun 8, 2026-

Related Health Care companies

All Health Care →

CRL SEC filings: frequently asked questions

Are CRL insiders buying or selling?

In the last 90 days, Charles River Laboratories (CRL) officers, directors and 10% owners reported 1 open-market purchase worth $2,974 by 1 insider and 4 open-market sales worth $19.5 million by 2 insiders on Form 4, a net sale of $19.5 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CRL stock?

As of September 30, 2026, the largest Charles River Laboratories (CRL) holders among the 13F filers tracked by SignalX were BlackRock ($1.1 billion), Vanguard Capital Management LLC ($922.7 million), T. Rowe Price Group ($887.4 million), Vanguard Portfolio Management LLC ($645.8 million), State Street Corp ($552.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CRL's revenue in fiscal year 2025?

For the fiscal year ended December 27, 2025 (FY2025), Charles River Laboratories (CRL) reported revenue of $4.0 billion (down 0.9% from FY2024) and a net loss of $144.3 million. Diluted EPS was -$2.91. The figures come from the XBRL data in the 10-K.

What are the main risks in CRL's latest 10-K?

In the 10-K filed February 18, 2026, Charles River Laboratories (CRL) flagged: Cybersecurity risk governance by Board Audit Committee with quarterly reviews and direct CIO, CISO reporting to Audit Chair. Heavy reliance on Chief Information Officer with 30+ years experience for global IT risk oversight and digital strategy execution. (AI summary of the Risk Factors section.)

What did CRL report in its latest 8-K?

Charles River Laboratories (CRL) filed an 8-K on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure). Acquisition agreement for Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania.

What are the latest CRL SEC filings?

Charles River Laboratories (CRL) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 9, 2026.

What is CRL's SEC CIK number?

Charles River Laboratories (CRL)'s SEC Central Index Key (CIK) is 1100682. EDGAR lists every CRL filing under that number.

Ask anything about CRL

The research agent reads CRL's filings, financials, insider trades and 13F holders, then answers with sources.